<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04039477</url>
  </required_header>
  <id_info>
    <org_study_id>KZR-616-005</org_study_id>
    <nct_id>NCT04039477</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP</brief_title>
  <acronym>MARINA</acronym>
  <official_title>A Phase 2 Randomized, Dose-blind, Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Autoimmune Hemolytic Anemia (AIHA) and Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kezar Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kezar Life Sciences, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 randomized, dose-blind, multicenter study designed to evaluate the safety,
      tolerability, efficacy, Pharmacokinetics (PK), and Pharmacodynamics (PD) of treatment with
      KZR-616 in patients with active Autoimmune Hemolytic Anemia or Immune Thrombocytopenia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from Baseline to Week 13 in hematologic parameters of interest in evaluable patients (Hgb for AIHA; Platelets [PLT] for ITP)</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline to Week 13 in hematologic parameters of interest (Hgb for AIHA; PLT for ITP) in the intent to treat (ITT) population</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline over time in hematologic parameters of interest (Hgb for AIHA; PLT for ITP)</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a response at Week 13</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients over time with a response</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients over time with loss of response</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients over time with sustained response</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline over time in Hct</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline over time in Lactate Dehydrogenase (LDH)</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline over time in Patient Global Assessment scores</measure>
    <time_frame>Baseline and every 4 weeks for 25 weeks</time_frame>
    <description>The PtGA is a visual analog scale (VAS) ranging from 0 to 100. Patients will provide a global rating of their disease, for the day of the visit, in response to the statement &quot;Considering all the ways that your disease affects you, please rate how you are feeling today by clicking or tapping on the line:&quot; using a 100-point VAS where 0 is &quot;very good, no symptoms&quot; and 100 is &quot;very poor, very severe symptoms.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For AIHA: Proportion of patients with an Hgb &gt;12 g/dL or 2 g/dL higher than Baseline at W13</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For AIHA: Number of blood transfusions and units of blood administered over time</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For ITP: Number of platelet transfusions and units of platelets administered over time</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of KZR-616 in patients with AIHA or ITP as assessed by monitoring incidence and severity of adverse events (AEs)</measure>
    <time_frame>Through study completion, up to 25 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) following KZR-616 injection</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) following KZR-616 injection</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak plasma concentration (Tmax) following KZR-616 injection</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak plasma concentration (Tmax) following KZR-616 injection</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) following KZR-616 injection</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) following KZR-616 injection</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2) following KZR-616 injection</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (T1/2) following KZR-616 injection</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Autoimmune Hemolytic Anemia</condition>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Arm A - KZR-616 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KZR-616 30mg Subcutaneous (SC) injection weekly for 13 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - KZR-616 45mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KZR-616 30 mg SC injection weekly for 1 dose then 45mg weekly for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KZR-616</intervention_name>
    <description>Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 1 week then 45 mg for 12 weeks</description>
    <arm_group_label>Arm A - KZR-616 30mg</arm_group_label>
    <arm_group_label>Arm B - KZR-616 45mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients must be at least 18 years of age at the time of signing informed
             consent at Screening

          2. Body Mass Index (BMI) equal to or greater than 18 kg/m2

          3. Have a documented diagnosis of AIHA, ITP, or Evans syndrome

          4. AIHA or ITP disease activity as follows::

               1. ITP: Per laboratory assessments on 2 separate occasions ≥7 days apart during
                  Screening, a mean Platelet (PLT) ≤30×109/L with no individual PLT &gt;35×109/L; or
                  for those patients receiving a constant dose of permitted treatments for ITP: a
                  mean PLT &lt;50×109/L, with no count &gt;55×109/L

               2. AIHA: Hgb ≤10 g/dL and presence of any 2 of the following:

             i. Haptoglobin &lt;lower limit of normal (LLN) ii. Corrected reticulocyte count &gt;upper
             limit of normal (ULN) iii. LDH &gt;ULN iv. Indirect bilirubin &gt;ULN.

          5. Documented inadequate response on intolerance to ≥1 standard treatment approach for
             AIHA or ≥2 standard treatment approaches for ITP

        Exclusion Criteria:

          1. Systemic Lupus Erythematosus with confirmed anti-phospholipid antibody syndrome, the
             presence of positive lupus anti-coagulant test, moderate-high titer anti-cardiolipin
             IgG or IgM or moderate-high titer anti-beta2-globuilin IgG or IgM or severe central
             nervous system involvement

          2. History of clinically significant coagulopathy, hereditary thrombocytopenia, anemia,
             or family history of thrombocytopenia

          3. History of primary immunodeficiency

          4. Use of nonpermitted medications within the specified washout periods prior to
             screening

          5. Recent serious or ongoing infection, or risk for serious infection

          6. Any of the following laboratory values at Screening:

               1. Estimated glomerular filtration rate (eGFR) &lt;45 ml/min

               2. Absolute neutrophil count (ANC) &lt;1.5×109/L (1500/mm3)

               3. Serum aspartate transaminase (AST), serum alanine transaminase (ALT) or serum
                  alkaline phosphatase &gt;2.5×ULN

               4. Thyroid stimulating hormone if outside of the central laboratory normal range and
                  considered clinically significant

               5. International normalized ratio (INR) or activated partial thromboplastin time
                  (aPTT) &gt;1.5×ULN

               6. Immunoglobulin G (IgG) &lt;500 mg/dL

               7. For ITP patients only: total bilirubin &gt;1.5×ULN (3×ULN for patients with
                  documented Gilbert's syndrome).

          7. Presence of New York Heart Association Class III or IV heart failure, or uncontrolled
             blood pressure, or prolonged QT interval

          8. Major surgery within 12 weeks before Screening or planned during the study period

          9. History of any thrombotic or embolic event within 12 months prior to Screening

         10. Clinical evidence of significant unstable or uncontrolled diseases

         11. Any active or suspected malignancy or history of documented malignancy within the last
             5 years before Screening, except appropriately excised and cured cervical carcinoma in
             situ or basal or squamous cell carcinoma of the skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kezar</last_name>
    <role>Study Director</role>
    <affiliation>Kezar Life Sciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Operations</last_name>
    <phone>(650)822-5600</phone>
    <email>clinicaltrials@kezarbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR-616 Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>KZR Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune</keyword>
  <keyword>Hemolytic</keyword>
  <keyword>Anemia</keyword>
  <keyword>Autoimmune Hemolytic Anemia</keyword>
  <keyword>AIHA</keyword>
  <keyword>Immune</keyword>
  <keyword>Thrombocytopenia</keyword>
  <keyword>Immune Thrombocytopenia</keyword>
  <keyword>ITP</keyword>
  <keyword>Blood disorders</keyword>
  <keyword>Hematology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Anemia, Hemolytic, Autoimmune</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

